Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

(Reuters) -German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

In the second quarter, Pfizer reported adjusted diluted earnings per share of $0.78 on revenue of nearly $14.7 billion. Both ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

And better still, healthy and growing dividend-paying stocks tend to increase their payouts over time. Pfizer's total annual ...

Contract Development and Manufacturing Organizations (CDMOs) have carved out a lucrative niche within the biopharma industry, ...

The Score is a weekly review of the biggest stock moves and the news that drove them. Here is this week's installment: ...

Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.